Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis - PubMed (original) (raw)
. 2003 Jul 1;102(1):161-8.
doi: 10.1182/blood-2002-12-3793. Epub 2003 Mar 20.
Affiliations
- PMID: 12649136
- DOI: 10.1182/blood-2002-12-3793
Free article
Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis
Yu-Ping Xia et al. Blood. 2003.
Free article
Abstract
Gene therapy approaches involving vascular endothelial growth factor (VEGF) to promote therapeutic angiogenesis are under consideration for conditions ranging from ischemic heart disease to nonhealing skin ulcers. Here we make the surprising observation that the transgenic delivery of VEGF to the skin results in a profound inflammatory skin condition with many of the cellular and molecular features of psoriasis, including the characteristic vascular changes, epidermal alterations, and inflammatory infiltrates. Even longstanding psoriatic disease remains dependent on the transgenic VEGF in this model because it can be effectively reversed by the addition of VEGF Trap, a potent VEGF antagonist. Previous attempts to faithfully replicate the psoriatic phenotype through the transgenic delivery of epidermal keratinocyte growth factors or inflammatory mediators generated phenotypes with only partial resemblance to human psoriasis, leaving unanswered questions about the etiology of this disease. The ability of transgenic VEGF to induce a psoriasiform phenotype suggests a new etiology and treatment approach for this disease and further substantiates emerging concerns about possible proinflammatory adverse effects that might be associated with therapeutic attempts to deliver VEGF.
Similar articles
- Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.
Rajagopalan S, Mohler ER 3rd, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH. Rajagopalan S, et al. Circulation. 2003 Oct 21;108(16):1933-8. doi: 10.1161/01.CIR.0000093398.16124.29. Epub 2003 Sep 22. Circulation. 2003. PMID: 14504183 Clinical Trial. - Intraventricular infusion of vascular endothelial growth factor promotes cerebral angiogenesis with minimal brain edema.
Harrigan MR, Ennis SR, Masada T, Keep RF. Harrigan MR, et al. Neurosurgery. 2002 Mar;50(3):589-98. doi: 10.1097/00006123-200203000-00030. Neurosurgery. 2002. PMID: 11841728 - Local perivascular application of low amounts of a plasmid encoding for vascular endothelial growth factor (VEGF165) is efficient for therapeutic angiogenesis in pigs.
Nikol S, Engelmann MG, Pelisek J, Fuchs A, Golda A, Shimizu M, Mekkaoui C, Rolland PH. Nikol S, et al. Acta Physiol Scand. 2002 Oct;176(2):151-9. doi: 10.1046/j.1365-201X.2002.01018.x. Acta Physiol Scand. 2002. PMID: 12354175 - Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards.
Epstein SE, Fuchs S, Zhou YF, Baffour R, Kornowski R. Epstein SE, et al. Cardiovasc Res. 2001 Feb 16;49(3):532-42. doi: 10.1016/s0008-6363(00)00217-0. Cardiovasc Res. 2001. PMID: 11166266 Review. - Induction of vascular networks in adult organs: implications to proangiogenic therapy.
Dor Y, Djonov V, Keshet E. Dor Y, et al. Ann N Y Acad Sci. 2003 May;995:208-16. doi: 10.1111/j.1749-6632.2003.tb03224.x. Ann N Y Acad Sci. 2003. PMID: 12814953 Review.
Cited by
- The Future Landscape of Endothelial Cells Research in Psoriasis: Bibliometric Analysis and Literature Review.
Long SY, Shang L, Shi H, Zhao S, Cao J, He Y. Long SY, et al. Clin Cosmet Investig Dermatol. 2023 Oct 30;16:3107-3120. doi: 10.2147/CCID.S435085. eCollection 2023. Clin Cosmet Investig Dermatol. 2023. PMID: 37927385 Free PMC article. - Inhibition of vascular endothelial growth factor-A downregulates angiogenesis in psoriasis: A pilot study.
Luengas-Martinez A, Ismail D, Paus R, Young HS. Luengas-Martinez A, et al. Skin Health Dis. 2023 May 15;3(5):e245. doi: 10.1002/ski2.245. eCollection 2023 Oct. Skin Health Dis. 2023. PMID: 37799359 Free PMC article. - Assessing the Association between Psoriasis and Cardiovascular Ischemia: An Investigation of Vascular Endothelial Growth Factor, Cutaneous Angiogenesis, and Arterial Stiffness.
Mohta A, Mohta A, Ghiya BC. Mohta A, et al. Indian Dermatol Online J. 2023 Aug 10;14(5):653-657. doi: 10.4103/idoj.idoj_246_23. eCollection 2023 Sep-Oct. Indian Dermatol Online J. 2023. PMID: 37727549 Free PMC article. - An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients.
Orzan OA, Țieranu CG, Olteanu AO, Dorobanțu AM, Cojocaru A, Mihai MM, Popa LG, Gheorghiu AM, Giurcăneanu C, Ion A. Orzan OA, et al. Pharmaceutics. 2023 Aug 21;15(8):2171. doi: 10.3390/pharmaceutics15082171. Pharmaceutics. 2023. PMID: 37631384 Free PMC article. Review. - Intestinal dysbiosis exacerbates the pathogenesis of psoriasis-like phenotype through changes in fatty acid metabolism.
Zhao Q, Yu J, Zhou H, Wang X, Zhang C, Hu J, Hu Y, Zheng H, Zeng F, Yue C, Gu L, Wang Z, Zhao F, Zhou P, Zhang H, Huang N, Wu W, Zhou Y, Li J. Zhao Q, et al. Signal Transduct Target Ther. 2023 Jan 30;8(1):40. doi: 10.1038/s41392-022-01219-0. Signal Transduct Target Ther. 2023. PMID: 36710269 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases